The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study

Journal of Substance Abuse Treatment

Volumn 62, Issue , 2016, Pages 62-67

  Knudsen, Hannah K ^a   Roman, Paul M ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Acamprosate; Affordable care act; Alcohol use disorder; Health reform; Insurance; Medicaid

Indexed keywords

ACAMPROSATE; DRUGS USED IN THE TREATMENT OF ADDICTION; TAURINE;

ALCOHOL-RELATED DISORDERS; ANALOGS AND DERIVATIVES; DRUG DEPENDENCE TREATMENT; HEALTH CARE POLICY; HUMAN; INSURANCE; LONGITUDINAL STUDY; MEDICAID; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ALCOHOL DETERRENTS; ALCOHOL-RELATED DISORDERS; HUMANS; INSURANCE CARRIERS; LONGITUDINAL STUDIES; MEDICAID; PATIENT PROTECTION AND AFFORDABLE CARE ACT; SUBSTANCE ABUSE TREATMENT CENTERS; TAURINE; UNITED STATES;

EID: 84955627963     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2015.10.005     Document Type: Article

References (44)

1. Abraham A.J., Knudsen H.K., Rieckmann T., Roman P.M. Disparities in access to physicians and medications for the treatment of SUDs between publicly and privately funded treatment programs. Journal of Studies on Alcohol and Drugs 2013, 74:258-265.
2. Abraham A.J., Knudsen H.K., Rothrauff T.C., Roman P.M. The adoption and implementation of alcohol pharmacotherapies in the Clinical Trials Network: The influence of research network participation. Journal of Substance Abuse Treatment 2010, 38:275-283.
3. Andrews C.M. The relationship of state Medicaid coverage to Medicaid acceptance among substance abuse providers in the United States. Journal of Behavioral Health Service and Research 2014, 41:460-472.
4. Bao Y., Casalino L.P., Pincus H.A. Behavioral health and health care reform models: Patient-centered medical home, health home, and accountable care organization. Journal of Behavioral Health Services and Research 2013, 40:121-132.
5. Beronio K., Glied S., Frank R. How the Affordable Care Act and Mental Health Parity and Addiction Equity Act greatly expand coverage of behavioral health care. Journal of Behavioral Health Services and Research 2014, 41:410-428.
6. Berry K.N., Huskamp H.A., Goldman H.H., Barry C.L. A tale of two states: Do consumers see mental health insurance parity when shopping on state exchanges?. Psychiatric Services 2015, 66:565-567.
7. Buck J.A. The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Affairs (Millwood) 2011, 30:1402-1410.
8. Buttorff C., Andersen M.S., Riggs K.R., Alexander G.C. Comparing employer-sponsored and federal exchange plans: Wide variations in cost sharing for prescription drugs. Health Affairs (Millwood) 2015, 34:467-476.
9. Cantor J.C., Monheit A.C., DeLia D.D., Lloyd K. Early impact of the Affordable Care Act on health insurance coverage of young adults. Health Services Research 2012, 47:1773-1790.
10. Carmen B., Angeles M., Ana M., Maria A.J. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction 2004, 99:811-828.
11. Cummings J.R., Wen H., Ko M., Druss B.G. Race/ethnicity and geographic access to Medicaid substance use disorder treatment facilities in the United States. JAMA Psychiatry 2014, 71:190-196.
12. D'Aunno T., Pollack H.A., Frimpong J.A., Wuchiett D. Evidence-based treatment of opioid disorders: A 23-year national study of methadone dose levels. Journal of Substance Abuse Treatment 2014, 47:245-250.
13. Diggle P.J., Liang K.Y., Zeger S.L. Analysis of longitudinal data 1994, Oxford University Press, Oxford, UK.
14. Ducharme L.J., Knudsen H.K., Roman P.M. Trends in the adoption of medications for alcohol dependence. Journal of Clinical Pharmacology 2006, 26:S13-S19.
15. Frank R.G., Beronio K., Glied S.A. Behavioral health parity and the Affordable Care Act. Journal of Social Work in Disability & Rehabilitation 2014, 13:31-43.
16. Garfield R.L., Druss B.G. Health reform, health insurance, and mental health care. The American Journal of Psychiatry 2012, 169:675-677.
17. Garner B.R. Research on the diffusion of evidence-based treatments within substance abuse treatment: A systematic review. Journal of Substance Abuse Treatment 2009, 36:376-399.
18. Ghitza U.E., Tai B. Challenges and opportunities for integrating preventive substance-use-care services in primary care through the Affordable Care Act. Journal of Health Care for the Poor and Underserved 2014, 25:36-45.
19. Glasner-Edwards S., Rawson R. Evidence-based practices in addiction treatment: Review and recommendations for public policy. Health Policy 2010, 97:93-104.
20. Henry J.Kaiser Foundation Health reform implementation timeline Retrieved May 1, 2014, from. http://kff.org/interactive/implementation-timeline/.
21. Kiefer F., Jahn H., Tarnaske T., Helwig H., Briken P., Holzbach R., Wiedemann K. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: A double-blind, placebo-controlled study. Archives of General Psychiatry 2003, 60:92-99.
22. Knudsen H.K., Abraham A.J., Roman P.M. Adoption and implementation of medications in addiction treatment programs. Journal of Addiction Medicine 2011, 5:21-27.
23. Knudsen H.K., Roman P.M. Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders. Journal of Studies on Alcohol and Drugs 2014, 75:467-475.
24. Knudsen, H. K., & Roman, P. M. (2015). Medicaid, private insurance, and the availability of smoking cessation interventions in substance use disorder treatment. Psychiatric Services, 66, 1213-1220.
25. Knudsen H.K., Roman P.M., Ducharme L.J. Does service diversification enhance organizational survival? Evidence from the private substance abuse treatment system. Journal of Behavioral Health Services and Research 2005, 32:241-252.
26. Knudsen H.K., Roman P.M., Oser C.B. Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations. Journal of Addiction Medicine 2010, 4:99-107.
27. Laudet A.B., Humphreys K. Promoting recovery in an evolving policy context: What do we know and what do we need to know about recovery support services?. Journal of Substance Abuse Treatment 2013, 45:126-133.
28. Maisel N.C., Blodgett J.C., Wilbourne P.L., Humphreys K., Finney J.W. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful?. Addiction 2013, 108:275-293.
29. Mark T.L., Wier L.M., Malone K., Penne M., Cowell A.J. National estimates of behavioral health conditions and their treatment among adults newly insured under ACA. Psychiatric Services 2015, 66:426-429.
30. Martinez M.E., Cohen R.A. Health insurance coverage: Early release of estimates from teh National Health Interview Survey, January-June 2014 2014, Natioanal Health Interview Survey Early Research Program, (Retrieved April 12, 2015, from https://web.archive.org/web/20150331191851/http://www.cdc.gov/nchs/data/nhis/earlyrelease/insur201412.pdf).
31. McCormick K.A., Cochran N.E., Back A.L., Merrill J.O., Williams E.C., Bradley K.A. How primary care providers talk to patients about alcohol - A qualitative study. Journal of General Internal Medicine 2006, 21:966-972.
32. McLellan A.T., Woodsworth A.M. The Affordable Care Act and treatment for "substance use disorders:" Implications of ending segregated behavioral healthcare. Journal of Substance Abuse Treatment 2014, 46:541-545.
33. Molfenter T., Capoccia V.A., Boyle M.G., Sherbeck C.K. The readiness of addiction treatment agencies for health care reform. Substance Abuse Treatment, Prevention, and Policy 2012, 7:16.
34. Morley K.C., Teesson M., Reid S.C., Sannibale C., Thomson C., Phung N., Haber P.S. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 2006, 101:1451-1462.
35. Pating D.R., Miller M.M., Goplerud E., Martin J., Ziedonis D.M. New systems of care for substance use disorders: Treatment, finance, and technology under health care reform. The Psychiatric Clinics of North America 2012, 35:327-356.
36. Richardson K., Baillie A., Reid S., Morley K., Teesson M., Sannibale C., Haber P. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?. Addiction 2008, 103:953-959.
37. Roman P.M., Abraham A.J., Knudsen H.K. Using medication-assisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation. Addictive Behaviors 2011, 36:584-589.
38. Roy A.K., Miller M.M. The medicalization of addiction treatment professionals. Journal of Psychoactive Drugs 2012, 44:107-118.
39. Sommers B.D., Buchmueller T., Decker S.L., Carey C., Kronick R. The Affordable Care Act has led to significant gains in health insurance and access to care for young adults. Health Affairs (Millwood) 2013, 32:165-174.
40. Sommers B.D., Gunja M.Z., Finegold K., Musco T. Changes in self-reported insurance coverage, access to care, and health under the Affordable Care Act. JAMA 2015, 314:366-374.
41. Tai B., Volkow N.D. Treatment for substance use disorder: Opportunities and challenges under the Affordable Care Act. Social Work in Public Health 2013, 28:165-174.
42. Terry-McElrath Y.M., Chriqui J.F., McBride D.C. Factors related to Medicaid payment acceptance at outpatient substance abuse treatment programs. Health Services Research 2011, 46:632-653.
43. White I.R., Royston P., Wood A.M. Multiple imputation using chained equations: Issues and guidance for practice. Statistics in Medicine 2011, 30:377-399.
44. Whitworth A.B., Fischer F., Lesch O.M., Nimmerrichter A., Oberbauer H., Platz T., Fleischhacher W.W. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996, 347:1438-1442.